Endocrinology

Your daily dose of the clinical news you may have missed.

Review the ACC/AHA guidelines on prevention of ASCVD through lifestyle and risk factor assessment and management in our at-a-glance slide show.

Cardiovascular mortality has been increasing among middle-aged US adult since 2011; a new study looked at changes in CV risk factors by income level over the past 20 years.

Chiadi Ndumele, MD, PhD, MHS, offers 3 thoughts for primary care on incorporating CKM syndrome screening into daily clinical practice.

"Primary care physicians... really are like the quarterbacks" for initiating multidisciplinary care for CKM syndrome, says Dr Chiadi Ndumele.

Absolute risk assessment for CVD remains the corner-stone of clinical primary prevention efforts. The new AHA prediction models expand that foundation.

Your daily dose of the clinical news you may have missed.

Managing cardiovascular-kidney-metabolic syndrome on a population-wide basis requires that social determinants of health be treated like any other risk factor, according to Ndumele.

Dr Chiadi Ndumele explains the need for the more comprehensive and also nuanced qualitative approach to estimating long-term CVD risk.

Chiadi Ndumele, MD, PhD, MHS, of Johns Hopkins University, details features of the new 4-stage construct that guides CKM diagnosis and promotes early disease intervention.

The second GLP-1 mimetic-based drug approved for chronic weight management, tirzepatide may outperform semaglutide, the first.

NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.

Your daily dose of the clinical news you may have missed.

Tirzepatide could help individuals who lose weight with lifestyle change to maintain and augment that loss, a well known challenge among persons with obesity.

The 2 highest doses of tirzepatide were ranked most likely to be effective for weight management in persons without diabetes, followed by semaglutide 2.4 mg.

A new paradigm for reducing CV morbidity and mortality provides a comprehensive approach to comorbid metabolic disease including early detection and treatment.

The phase 3 semaglutide kidney outcomes trial will be stopped immediately with FLOW read out expected in early 2024, the company said.

Your daily dose of the clinical news you may have missed.

In adults older than age 65 years with T2D, a simple clinical decision support tool plus shared decision making reduced hypoglycemic episodes by half.

Your daily dose of the clinical news you may have missed.

The addition of ileus as a potential adverse event associated with the GLP-1 mimetic is not the first required for the class by the regulator.

The prevalence of cardiac, renal, and metabolic conditions has significantly increased over 20 years and so has the number of US adults who have all 3.

Pivotal cardiovascular outcome trials that evaluated cardiorenal benefits of the newer classes were not designed to consider racial/ethnic variations, researchers state.

The biosimilar to the GLP-1 mimetic Victoza proved noninferior for reduction of HbA1c and had similar positive effects on body weight, lipids, and blood pressure.